secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verona Pharma plc (—)
CIK:        0001657312
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001104659-25-097318
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck completes acquisition of Verona Pharma for $107 per ADS
-------------------------------------------------------------

- Consideration: $13.375 per ordinary share ($107 per ADS) paid in cash.
- Nasdaq trading suspended Oct 7; company to file Form 25 for delisting and deregistration.
- All 10 directors resigned; Benjamin Lucas (PEO) and Ebru Can Temucin (PFO) appointed.
- Verona Pharma becomes an indirect wholly owned subsidiary of Merck.
- High Court sanctioned Scheme of Arrangement on Oct 6; transaction closed Oct 7.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657312/000110465925097318/0001104659-25-097318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657312/000110465925097318/tm2528100d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer